Issues related to risk evaluation and mitigation strategies in health-system pharmacy

Coffey, Justine
September 2010
American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1512
Academic Journal
The article presents the author's views on the issues focusing on the risk evaluation and mitigation strategies (REMSs) in health-system pharmacy. He is of the opinion that patient access to some medications could be compromised if the pharmacy's input and involvement in the development of REMSs is not considered. He believes that the U.S. Food and Drug Administration (FDA) should consult the pharmacists and utilize their expertise in addressing the issues that hinder the development of REMSs.


Related Articles

  • A renewed interest in compounding. Lunner, Kristina E. // Pharmacy Today;Sep2006, Vol. 12 Issue 9, p34 

    The article focuses on the pharmacist compounding, a core element of the practice of pharmacy, which has gained congressional interest. A briefing for Hill staff on pharmacist compounding was co-sponsored by the U.S. legislators. The briefing was designed to educate staff about the topic...

  • Fraud in the pharmacy? Pray, W. Steven // Drug Topics;Sep2014, Vol. 158 Issue 9, p12 

    The author discusses the fraud in pharmacy in the U.S. He mentions about the definition of health fraud by the U.S. Food and Drug Administration (FDA) as misleading advertisements and promotions of health care products. He states that inclusion of legitimate vitamins and minerals is missing in...

  • Letters from FDA. Richard, Carli // Pharmacy Today;May2008, Vol. 14 Issue 5, p45 

    The article focuses on the analysis conducted by pharmacists Tom Murry, executive director of the Pharmacy Compounding Accreditation Board on regulatory issues that affects compounding pharmacy in the U.S. It mentions that Murry reviewed ways that pharmacy, the government and how the courts deal...

  • FDA's Safe Use Initiative. Fritsch, Beth // Pharmacy Today;Sep2010, Vol. 16 Issue 9, p61 

    The article focuses on the usage of acetaminophen under the Safe Use Initiative of the U.S. Food and Drug Administration (FDA). It states that the function of the Safe Use Initiative is to reduce the possible harm of unregulated medication use. It also says that FDA has collaborated with the...

  • VA pursues bar-code quality. Young, Donna // American Journal of Health-System Pharmacy;7/1/2004, Vol. 61 Issue 13, p1312 

    Reports that the U.S. Food and Drug Administration is requiring linear bar codes on most prescription medications and nonprescription drugs commonly used in hospitals. Need for health systems to establish quality measures to ensure that bar codes on the products or on labels printed by a...

  • Review of eight restricted-access programs and potential implications for pharmacy. Evans, Jeffery D.; Evans, Emily W. // American Journal of Health-System Pharmacy;6/15/2007, Vol. 64 Issue 12, p1302 

    The article discusses several restricted-access programs and their implications for pharmacy in the U.S. It regulates those who may dispense, prescribe or take specific medications based on the safety data of the Food and Drug Administration (FDA). It introduces various restricted medication...

  • Letters. Wheelock, Anne; Prazenica, Jennifer; Katz, Robert S. // Drug Topics;Apr2012, Vol. 156 Issue 4, p4 

    Several letters to the editor are presented in response to articles in previous issues including pharmacists complaining about their job, in the November 2011 issue, retail setting in hospital pharmacy, and "New diet drug overwhelmingly endorsed by FDA committee," in the February 23, 2012 issue.

  • Potential Risks of Pharmacy Compounding. Gudeman, Jennifer; Jozwiakowski, Michael; Chollet, John; Randell, Michael // Drugs in R&D;2013, Vol. 13 Issue 1, p1 

    Pharmacy compounding involves the preparation of customized medications that are not commercially available for individual patients with specialized medical needs. Traditional pharmacy compounding is appropriate when done on a small scale by pharmacists who prepare the medication based on an...

  • Drug Labeling Seminar Provides Industry Updates.  // Townsend Letter for Doctors & Patients;May2004, Issue 250, p18 

    Presents information on the seminar sponsored by the American Association of Homeopathic Pharmacists in Washington, D.C. in September 2003. Focus of seminars on drug labeling requirements and the Food and Drug Administration and Federal Trade Commission's scrutiny of product label claims;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics